Numinus

Numinus Completes Acquisition of Neurology Centre of Toronto

• Post published:September 23, 2021
• Post category:Press Release

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology

• Post published:July 29, 2021
• Post category:Press Release

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD

• Post published:July 12, 2021
• Post category:Press Release

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology

• Post published:July 6, 2021
• Post category:Press Release

Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species

• Post published:June 24, 2021
• Post category:Press Release

Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange

• Post published:June 18, 2021
• Post category:Press Release

Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation

• Post published:May 13, 2021
• Post category:Press Release

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

• Post published:May 11, 2021
• Post category:Press Release

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD

• Post published:May 10, 2021
• Post category:Press Release

Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural Psilocybin Protocol

• Post published:May 4, 2021
• Post category:Press Release